Critical appraisal of commercially available suspending vehicles for extemporaneous compounding of cardiovascular medicines: physical and chemical stability mini review

References

• Alexander KS, Thyagarajapuram N. 2003. Formulation and accelerated stability studies for an extemporaneous suspension of amiodarone hydrochloride. Int J Pharm Compd. 7:389.
   PubMedGoogle Scholar
• Ali H, Saad R, Ahmed A, El-Haj B. 2016. Extemporaneous furosemide suspensions for pediatrics use prepared from commercially available tablets. Int J Curr Pharm Rev Res. 7:75–83.
   Google Scholar
• Allahham A, Stewart P, Marriott J, Mainwaring D. 2005. Factors affecting shear thickening behavior of a concentrated injectable suspension of levodopa. J Pharm Sci. 94:2393–2402.
   PubMed Web of Science ®Google Scholar
• Allen LV, Jr. 2008. Valsartan 4-mg/mL oral liquid. Int J Pharm Compd. 12:269.
   Google Scholar
• Amin A, Bourget P, Vidal F, Cartier F, Beauvais R, Afonso VoN. 2015. Physicochemical and microbiological stability of azathioprine in InOrpha suspending agent studied under various conditions. Int J Pharm Compd. 19:73–77.
   PubMedGoogle Scholar
• Asker AF, Ferdous AJ. 1996. Photodegradation of furosemide solutions. PDA J Pharm Sci Technol. 50:158–162.
   PubMedGoogle Scholar
• Aulton ME, Taylor K, et al. 2013. Aulton’s pharmaceutics the design and manufacture of medicines. In: Aulton ME, editor. Pharmaceutics. Edinburgh: Elsevier Health Sciences. Chapter 7:115–125.
   Google Scholar
• Berger-Gryllaki M, Podilsky G, Widmer M, Gloor S, Testa B, Pannatier A. 2007. The development of a stable oral solution of captopril for paediatric patients. Eur J Hosp Pharm Sci. 13:27–32.
   Google Scholar
• Bourget P, Amin A, Vidal F, Pieyre M, El Dosso O, Beauvais R, Loeuillet R. 2014. Physicochemical and microbiological stabilities of hydrocortisone in InOrpha suspending agent studied under various conditions. Int J Pharm Compd. 18:427–431.
   PubMedGoogle Scholar
• Brustugun J, Lao YE, Fagernaes C, Braenden J, Kristensen S. 2009. Long-term stability of extemporaneously prepared captopril oral liquids in glass bottles. Am J Health Syst Pharm. 66:1722–1725.
   PubMed Web of Science ®Google Scholar
• Buontempo F, Bernabeu E, Glisoni RJ, Quiroga E, Bregni C, Chiappetta DA. 2010. Carvedilol stability in paediatric oral liquid formulations. Farm Hosp. 34:293–297.
   PubMedGoogle Scholar
• Casas M, Álvarez J, Lucero MJ. 2015. Physicochemical stability of captopril and enalapril extemporaneous formulations for pediatric patients. Pharm Dev Technol. 20:271–278.
   PubMed Web of Science ®Google Scholar
• Dentinger PJ, Swenson CF, Anaizi NH. 2003. Stability of nifedipine in an extemporaneously compounded oral solution. Am J Health Syst Pharm. 60:1019–1019.
   PubMed Web of Science ®Google Scholar
• Fagron. (2016). Compounding Matters. Accessed June 2018. https://fagron.com/en/syrspendr-sf-publication-overview.
   Google Scholar
• Falconer JR, Steadman KJ. 2017. Extemporaneously compounded medicines. Aust Prescr. 40:5–8.
   PubMed Web of Science ®Google Scholar
• Geiger CM, Sorenson B, Whaley P. 2015. Stability assessment of 10 active pharmaceutical ingredients compounded in SyrSpend SF. Int J Pharm Compd. 19:420–427.
   PubMedGoogle Scholar
• Geiger CM, Sorenson B, Whaley PA. 2013. Stability of captopril in SyrSpend SF. Int J Pharm Compd. 17:336–338.
   PubMedGoogle Scholar
• Haywood A, Glass BD. 2013. Liquid dosage forms extemporaneously prepared from commercially available products - considering new evidence on stability. J Pharm Pharm Sci. 16:441–455.
   PubMed Web of Science ®Google Scholar
• ICH Harmonised Tripartite Guideline. 2003. Evaluation for Stability Data Q1E. Available from: http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
   Google Scholar
• Klovrzova S, Zahalka L, Kriz T, Zahalkova O, Matysova L, Sklubalova Z, Horak P. 2016. Extemporaneous sotalol hydrochloride oral solutions for use in paediatric cardiology: formulation and stability study. Eur J Hosp Pharm. 23:33–37.
   PubMedGoogle Scholar
• Kristensen S, Lao YE, Brustugun J, Braenden JU. 2008. Influence of formulation properties on chemical stability of captopril in aqueous preparations. Pharmazie. 63:872–877.
   PubMed Web of Science ®Google Scholar
• Lye MYF, Yow KL , Lim LY, Chan SY, Chan E, Ho PC. 1997. Effects of ingredients on stability of captopril in extemporaneously prepared oral liquids. Am J Health Syst Pharm. 54:2483–2487.
   PubMed Web of Science ®Google Scholar
• Musko M, Sznitowska M. 2014. Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan. Acta Pharm. 64:463.
   PubMed Web of Science ®Google Scholar
• Nahata MC, Allen LV, Jr, 2008. Extemporaneous drug formulations. Clin Ther. 30:2112–2119.
   PubMed Web of Science ®Google Scholar
• Perrigo company. 2018. “ORA-Blend.” Accessed January 23, 2018. https://www.perrigo.com/files/rx/pdfs/pds171-Ora%20Blend%20 Sell%20Sheet.pdf
   Google Scholar
• Polonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. 2016. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie. 71:185–191.
   PubMed Web of Science ®Google Scholar
• Polonini HC, Silva SL, de Almeida TR, Brandão MAF, Ferreira AO. 2016. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur J Hosp Pharm. 23:352–358.
   PubMedGoogle Scholar
• Potier A, Voyat J, Nicolas A. 2017. Stability study of a clonidine oral solution in a novel vehicle designed for pediatric patients. Pharm Dev Technol. 1–10. DOI: 10.1080/10837450.2017.1389955
   Web of Science ®Google Scholar
• Riahi S, Ambühl M, Stichler J, Bandilla D. 2015. Stability of refrigerated miglustat after preparation in InOrpha® flavored suspending excipient for compounding of oral solutions and suspensions. Drug Des Devel Ther. 9:561–566.
   PubMed Web of Science ®Google Scholar
• Sansom, L., editor. 2015. Australian pharmaceutical formulary and handbook. Vol. 23. Canberra, Australia: Pharmaceutical Society of Australia.
   Google Scholar
• Santoveña A, Charola I, Suárez-González J, Teigell-Pérez N, García-van Nood S, Soriano M, Fariña JB. 2016. Development of a novel physico-chemically and microbiologically stable oral solution of flecainide for pediatrics. Pharm Dev Technol. 1–8.
   PubMed Web of Science ®Google Scholar
• Santoveña A, Suarez-Gonzalez J, Martin-Rodriguez C, Farina JB. 2017. Formulation design of oral pediatric Acetazolamide suspension: dose uniformity and physico-chemical stability study. Pharm Dev Technol. 22:191–197.
   PubMed Web of Science ®Google Scholar
• Schlatter J, Bourguignon E, Majoul E, Kabiche S, Balde IB, Cisternino S, Fontan JE. 2017. Stability study of oral pediatric idebenone suspensions. Pharm Dev Technol. 22:296–299.
   PubMed Web of Science ®Google Scholar
• Shoosanglertwijit J, Kaewnopparat S, Yongmaitreesakul B, Pattayananthavej S, Kaewnopparat N. 2011. Physical, chemical, and microbiological stability of extemporaneous furosemide suspensions. Asian Biomed. 5:681–686.
   Web of Science ®Google Scholar
• Sidhom MB, Rivera N, Almoazen H, Taft DR, Kirschenbaum HL. 2005. Stability of sotalol hydrochloride in extemporaneously prepared oral suspension formulations. Int J Pharm Compd. 9:402–406.
   PubMedGoogle Scholar
• Timmins P, Jackson IM, Wang YcJ. 1982. Factors affecting captopril stability in aqueous solution. Int J Pharm. 11:329–336.
   Web of Science ®Google Scholar
• van Riet-Nales DA, Schobben AFAM, Vromans H, Egberts TCG, Rademaker CMA. 2016. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects. Arch Dis Child. 101:662–669.
   PubMed Web of Science ®Google Scholar
• Yag N, Kenmotsu H, Sekikawi H, Takada M. 1991. Studies on the photolysis and hydrolysis of furosemide in aqueous solution. Chem Pharm Bull. 39:454–457.
   Web of Science ®Google Scholar
• Zerbit J, Bordenave J, Benoit G. 2015. Physicochemical and microbiological stability studies of a melatonin oral suspension in a commercially available vehicle for paediatric use. Eur J Hosp Pharm. 22:89–93.
   Google Scholar